AbbVie Prices Arthritis Drug at $59,000 a Year

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

Read Full Article »
Show comments Hide Comments

Related Articles